Eppendorf advances bioprocess monitoring and analysis with the launch of the BioNsight cloud software

Register for free to listen to this article
Listen with Speechify
0:00
5:00

Original story from Eppendorf.

Hamburg, July 2024 

Data is the key to bioprocess development today. It is needed to understand which critical process parameters influence the growth of the cells, product yield, and critical quality attributes, or in short, to develop successful processes quickly. Bioprocess data from different batches, generated by different inline sensors and external analyzers, are like individual pieces of a puzzle. Eppendorf launches BioNsight cloud, a new cloud-based software solution for bioprocess monitoring and analysis. It makes it easy to consolidate and analyze bioprocess data in one central location, helping to solve the puzzle and transfer data to insights. 

BioNsight cloud is fully integrated into the Eppendorf Bioprocess control software DASware® control 6. This enables automized data transfer from DASware control 6 to the cloud in real-time. The upload of offline data from external analyzers, data from historic runs, and process data from nonEppendorf bioprocess controllers is possible as well. 

 An illustration of how Eppendorf's BioNsight cloud software works
credit: eppendorf

Analyze and build on the data: Data can be contextualized to gain even further insights: Data from different batches can be easily synchronized and compared, making it easier to identify patterns across runs and scales, accelerating the development process, and ensuring consistent quality and performance. 

Monitor remotely: BioNsight cloud facilitates the remote monitoring of bioprocesses, which are controlled by the Eppendorf bioprocess control software DASware control 6. So, users always know how the bioprocess runs are performing and can make the right decisions faster, while the process is still running.

Simplify access and collaboration: The bioprocess data in BioNsight cloud is accessible from everywhere, by everyone the owner authorizes. BioNsight cloud was developed with the highest standards of data security in mind. Hosted and built up on Microsoft® Azure technology it gives the user the peace of mind that the data is well protected, yet accessible. 

Jill Perez, Senior Scientist at Solugen, USA evaluated the product during its development and summarizes its value: “BioNsight cloud has proven to be invaluable in its capacity to store every fermentation run, facilitating comparisons across all tank data. Its online functionality enables real-time viewing of runs, accessible even on mobile devices. Additionally, the graphing feature simplifies the plotting of data, enabling effortless comparison between past and present runs.” 

https://www.eppendorf.group/BioNsight-cloud 

About Eppendorf Group 

Eppendorf is a leading international life science company that develops, manufactures, and distributes instruments, consumables, and services for use in laboratories around the world. The product portfolio of the business units Liquid Handling & Consumables, Separation & Instrumentation and Bioprocess includes, for example, pipettes, pipette tips, centrifuges, mixers, ultra-freezers and bioreactors for cell and gene research. In addition, Eppendorf offers a wide range of high-quality consumables. In fiscal year 2023, the Eppendorf Group generated €1.08 billion in sales and invested €69 million in research and development (R&D). Eppendorf products are used in academic or industrial research laboratories, such as pharmaceutical, biotech, chemical, and food industries, as well as clinical, environmental, forensic, and industrial laboratories for process analysis, production, and quality assurance. Since 1945, the Eppendorf Group has been headquartered in Hamburg, Germany, and today operates production and R&D sites in Europe, Asia and North America and has subsidiaries in 33 countries. Today, the Group employs more than 5,000 people worldwide. They all act in accordance with the purpose of the company's founders: to improve human living conditions.

www.eppendorf.com



This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release republishing policy can be accessed here.



Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

September 2024 front cover

Latest Issue  

• Volume 20 • Issue 5 • September 2024

September 2024

September 2024 Issue